Publikationen, an denen er mitarbeitet Francisco de Borja Hernández Breijo (7)

2022

  1. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

2017

  1. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease

    Biomarkers, Vol. 22, Núm. 2, pp. 133-144

2014

  1. Effect of Infliximab in oxidised serum albumin levels during experimental colitis

    Biomarkers, Vol. 19, Núm. 8, pp. 693-701

2013

  1. Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1

    Toxicology and Applied Pharmacology, Vol. 272, Núm. 3, pp. 568-578

2012

  1. Is the autophagy induced by thiopurines beneficial or deleterious?

    Current Drug Metabolism, Vol. 13, Núm. 9, pp. 1267-1276

2011

  1. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma

    World Journal of Gastroenterology, Vol. 17, Núm. 34, pp. 3899-3911

2009

  1. RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-α-induced cell death in hepatocarcinoma cancer cell lines

    Journal of Cellular Biochemistry, Vol. 108, Núm. 6, pp. 1292-1301